Wanda French-Brown is an accomplished litigator who brings a creative and analytical approach to each matter, focusing on the overall picture to develop litigation strategies that align with her clients’ business objectives. Wanda has represented clients in patent infringement matters in federal courts, the U.S. International Trade Commission, and Patent Trial and Appeal Board.
Wanda has broad technological knowledge, regularly representing clients in a range of technologies, including wireless communication and mobile devices, LCD and LED, biotechnology, medical devices, health care diagnostics, and pharmaceuticals with a concentration in Hatch-Waxman litigation.
With a decade of experience working as a registered pharmacist in the health care and pharmaceutical fields, Wanda is well-versed in Food and Drug Administration guidelines created by the Hatch-Waxman and Biologics Price Competition and Innovation acts, which are crucial to the entry of generic and biosimilar pharmaceutical products. Wanda counsels pharmaceutical clients about the scope and coverage of patents, new drug product exclusivity, and litigation strategies related to Paragraph IV certifications filed under the Hatch-Waxman Act.
Select examples of Wanda’s prior firm experience include:
- Represented multiple biotechnology companies before the Federal Circuit involving an appeal from a final decision in an inter partes review proceeding before the Patent Trial and Appeal Board.
- Represented a pharmaceutical company in Hatch-Waxman 505(b)(2) patent litigation involving the drug pemetrexed. Achieved a claim construction victory, which resulted in a favorable settlement before the end of a 7-day bench trial.
- Represented an American pharmaceutical company in Hatch-Waxman ANDA patent litigation involving its kinase inhibitor products. The court adopted proposed constructions for all 15 terms in dispute. The case resulted in a favorable settlement for the client.
- Represented a leading multinational technology corporation in a Section 337 proceeding before the U.S. International Trade Commission in a patent infringement action involving LTE and 3GPP technology, which resulted in a favorable settlement.
- Represented the complainant in a Section 337 proceeding before the U.S. International Trade Commission in a patent infringement action involving Liquid Crystal Display (LCD) technology.
- Represented an American pharmaceutical company in patent infringement action involving pharmaceutical products for the treatment of hepatitis C virus infection. Obtained a claim construction ruling in favor of the client, which resulted in a win on summary judgment for infringement.
- Represented a defendant in a Section 337 proceedings before the U.S. International Trade Commission in a patent infringement action involving LED (Light Emitting Diode) technology and products.
- Represented an international based pharmaceutical company in a patent litigation involving Polymerase chain reaction (PCR) diagnostic testing kits.
- Represented a British pharmaceutical company in patent infringement litigation involving its antidepressant products, which resulted in a favorable settlement.
- Represented a U.S.-based pharmaceutical company in Hatch-Waxman ANDA patent litigation involving its antihistamine products against 21 generic defendants. Obtained consent judgments with injunctions against all defendants.
- Represented a medical device manufacturer in defense of patent infringement involving fiberoptic intra-aortic balloon catheters and pumps. Developed a pretrial strategy that resulted in a favorable settlement agreement shortly after serving invalidity contentions and before the start of fact discovery.
- Represented a packaged food products company in inter partes review petitions before the U.S. Patent and Trademark Office while concurrently defending the client in a district court patent infringement action and a writ of mandamus appeal before the Federal Circuit.
- Represented a financial services company in defense of patent infringement involving its prepaid card products. Successfully eliminated a claim against the defendant for over $100 million in past damages and future royalties.
- Seton Hall University Law School, 法学博士, magna cum laude, Intellectual Property Law Concentration
- Rutgers University College of Pharmacy, 学士
- U.S. District Court for the District of New Jersey
- New Jersey
- Named "Best Lawyer" in Intellectual Property Litigation by The Best Lawyers in America, published by Woodward White, Inc. (2023)
- Named to the "Most Influential Black Lawyers" list, Savoy Magazine (2022)
- Named to “2020 Women of Influence,” New York Business Journal (2020)
- Named among The National Black Lawyers’ Top 100 list (2019-2020)
- Named to “New York Super Lawyers Rising Stars,” IP Litigation, Super Lawyers, Thomson Reuters (2016-2018)
- Named among The National Black Lawyers’ "Top 40 Under 40" list (2015)
- Lambda Legal Board of Directors
- Law360’s Intellectual Property Editorial Advisory Board (2020)
- International Trade Commission Trial Lawyers Association
- New York Intellectual Property Law Association
- American Bar Association: Intellectual Property Section
- New York City Bar Association
- Minorities in the Profession Committee (2015-2019)
- Diversity Pipeline Initiatives Committee (2013-2014)
- New Jersey Intellectual Property Law Association
- National LGBT Bar Association